Developing a new method to prevent pregnancy and HIV in adolescents assigned female at birth
Official title: RP5 MPT Study
Funded at Florida State University · NIH-10993609 · Data updated 2026-11-12
This study is looking to help young people assigned female at birth in the U.S. by creating a new way to prevent unplanned pregnancies and HIV, using a long-lasting shot that combines birth control and an HIV prevention drug, so they can have more options for staying healthy and safe.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida State University NIH-funded |
| Lab location | 1 site (Tallahassee, United States) |
| Project start | January 25, 2023 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $503,839 |
| NIH project number | 5UM2HD111102-03 |
| Project ID | NIH-10993609 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adolescents assigned female at birth, particularly those who are at risk for unplanned pregnancies or HIV.
✕Less likely to help
Patients who are not assigned female at birth or those who are not at risk for pregnancy or HIV may not benefit from this research.
What this research studies
This research focuses on addressing the unmet sexual and reproductive health needs of adolescents assigned female at birth (AFAB) in the U.S., particularly regarding unplanned pregnancies and HIV prevention. It aims to develop a multi-purpose prevention technology (MPT) that combines an injectable contraceptive with an HIV prevention drug, cabotegravir (CAB). The study will explore the preferences of AFAB adolescents for discreet and long-lasting prevention methods, utilizing a novel drug delivery system that could provide protection for at least three months. By engaging with this population, the research seeks to improve health outcomes and increase the uptake of preventive measures among youth.
Why it matters
Potential benefit: If successful, this research could provide a safe and effective method for preventing both unplanned pregnancies and HIV among adolescents assigned female at birth.
How similar studies have gone: Early studies have shown promise for similar approaches, particularly with the use of long-acting agents like cabotegravir for HIV prevention.
Where this research is happening
-
Florida State University
Tallahassee, United States Active
Researchers
- Principal investigator: Hightow-Weidman, Lisa B — Florida State University
- Study coordinator: Hightow-Weidman, Lisa B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.